Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228532 | 1.00 | LRRK2 (0.58) | LRRK2JAK2KDM4EALDH1A1MAPT | |
| SCHEMBL27228404 | 0.87 | SYK (0.47) | LRRK2KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL30914271 | 0.87 | SYK (0.47) | LRRK2KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL30860787 | 0.85 | SYK (0.46) | LRRK2JAK2KDM4EALDH1A1MAPT | |
| SCHEMBL27227816 | 0.85 | SYK (0.46) | LRRK2JAK2KDM4EALDH1A1MAPT | |
| SCHEMBL27228000 | 0.83 | LRRK2 (0.65) | LRRK2CYP1A2 | |
| SCHEMBL30860971 | 0.83 | LRRK2 (0.65) | LRRK2CYP1A2 | |
| SCHEMBL27380982 | 0.76 | LRRK2 (0.72) | LRRK2JAK2 | |
| SCHEMBL15585506 | 0.74 | SYK (0.46) | LRRK2KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL8312915 | 0.74 | CCR4 (0.55) | KMT2ACCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | LRRK2 1/4885JAK2 352/4885KDM4E 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.